Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.60 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.60 |
| ▸ | HTR2A | P28223 | 1/20 | 0.50 |
| ▸ | HTR2C | P28335 | 1/20 | 0.50 |
| ▸ | HTR2B | P41595 | 1/20 | 0.50 |
| ▸ | MC4R | P32245 | 2/20 | 0.47 |
| ▸ | MC5R | P33032 | 2/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | BCHE | P06276 | 1/20 | 0.46 |
| ▸ | ACHE | P22303 | 1/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.46 |
| ▸ | MC3R | P41968 | 1/20 | 0.44 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.44 |
| ▸ | PYCR1 | P32322 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL132340 | 0.81 | CYP1A2 (0.56) | CYP1A2CYP2A6HTR2AHTR2CHTR2B | |
| SCHEMBL2838141 | 0.79 | CYP1A2 (0.65) | CYP1A2CYP2A6HTR2AHTR2CHTR2B | |
| SCHEMBL29560700 | 0.79 | CYP1A2 (0.65) | CYP1A2CYP2A6HTR2AHTR2CHTR2B | |
| SCHEMBL6240981 | 0.79 | CYP1A2 (0.65) | CYP1A2CYP2A6HTR2AHTR2CHTR2B | |
| SCHEMBL132200 | 0.78 | SIGMAR1 (0.59) | CYP1A2CYP2A6HTR2AHTR2CHTR2B | |
| SCHEMBL720558 | 0.76 | CYP1A2 (0.56) | CYP1A2CYP2A6HTR2AHTR2CHTR2B | |
| SCHEMBL29955760 | 0.76 | CYP1A2 (0.56) | CYP1A2CYP2A6HTR2AHTR2CHTR2B | |
| SCHEMBL130903 | 0.76 | SIGMAR1 (0.58) | CYP1A2CYP2A6HTR2AHTR2CHTR2B | |
| SCHEMBL44621 | 0.75 | CYP2A6 (0.60) | CYP1A2CYP2A6HTR2AHTR2CHTR2B | |
| SCHEMBL7439598 | 0.75 | CYP1A2 (0.60) | CYP1A2CYP2A6HTR2AHTR2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 262 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9198426-B2 | Use of 5 pyridin-4-yl-1,3-thiazoles for controlling phytopathogenic fungi | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-12-01 | — | — | US | claimed |
| US-20100168185-A1 | Use of 5-pyridin-4-yl-1,3-thiazoles for controlling phytopathogenic fungi | BAYER CORPSCIENCE AG (DE) | 2010-07-01 | — | — | US | claimed |
| EP-2198710-A1 | Use of 5-pyridin-4yl-(1,3) thiazoles for combating phytopathogenic fungi | Bayer CropScience AG (DE) | 2010-06-23 | — | — | EP | claimed |
| EP-1412328-B1 | DOLASTATIN 10 DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2006-10-04 | — | — | EP | claimed |
| US-20050080261-A1 | Purine inhibitors of cyclin dependent kinase 2 and IkappaB-alpha | LUM ROBERT T (US) | 2005-04-14 | — | — | US | claimed |
| US-6737409-B2 | FOR CANCER THERAPY | HOFFMANN-LA ROCHE INC. | 2004-05-18 | — | — | US | claimed |
| EP-1412328-A1 | DOLASTATIN 10 DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2004-04-28 | — | — | EP | claimed |
| US-20030055002-A1 | Dolastatin 10 derivatives | HOFFMANN-LA ROCHE INC. | 2003-03-20 | — | — | US | claimed |
| WO-2003008378-A1 | DOLASTATIN 10 DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2003-01-30 | — | — | WO | claimed |
| EP-3689891-B1 | COBALT COMPLEX, PRODUCTION METHOD THEREFOR, AND CATALYST FOR HYDROSILYLATION REACTION | UNIV KYUSHU NAT UNIV CORP (JP) | 2023-03-01 | — | — | EP | disclosed |
| US-11591354-B2 | Thiamine compound, preparation method and pharmaceutical composition thereof | SHANGHAI RAISING PHARMACEUTICAL CO., LTD. (CN) | 2023-02-28 | — | — | US | disclosed |
| CN-107660202-B | Water-soluble prodrugs | 大日本住友制药肿瘤公司 | 2021-12-24 | — | — | CN | disclosed |
| EP-3889160-A1 | THIAMINE COMPOUND, PREPARATION METHOD AND PHARMACEUTICAL COMPOSITION THEREOF | Shanghai Raising Pharmaceutical Co., Ltd. (CN) | 2021-10-06 | — | — | EP | disclosed |
| CN-107406476-B | Mononuclear iron complex and organic synthesis reaction using same | 国立大学法人九州大学 | 2021-07-27 | — | — | CN | disclosed |
| EP-0279681-A2 | Saturated heterocyclic carboxamide derivatives | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 1988-08-24 | — | — | EP | disclosed |
| EP-0279781-A2 | Process for the preparation of 4-acetoxy-3-hydroxyethyl-acetidinone | CIBA-GEIGY AG (CH) | 1988-08-24 | — | — | EP | disclosed |
| EP-0214708-A2 | Griseolic acid derivatives, their preparation and their use | SANKYO COMPANY LIMITED (JP) | 1987-03-18 | — | — | EP | disclosed |
| US-4634706-A | BRAIN METABOLISM | SANKYO COMPANY LIMITED (JP) | 1987-01-06 | — | — | US | disclosed |
| EP-0143557-A2 | Griseolic acid derivatives, and their use | SANKYO COMPANY LIMITED (JP) | 1985-06-05 | — | — | EP | disclosed |
| EP-0056475-A2 | Pharmaceutical compositions | MERCK PATENT GmbH (DE) | 1982-07-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168185-A1 | Use of 5-pyridin-4-yl-1,3-thiazoles for controlling phytopathogenic fungi | PIR, PNPO, PDXK | CYP1A2 1420/4885CYP2A6 2384/4885HTR2A 3813/4885 |
| US-20050080261-A1 | Purine inhibitors of cyclin dependent kinase 2 and IkappaB-alpha | IKBKB, NFKB1, CDK4 | CYP1A2 2133/4885CYP2A6 2515/4885HTR2A 1109/4885 |
| US-20030055002-A1 | Dolastatin 10 derivatives | DAD1, DDOST, NPC1 | CYP1A2 2980/4885CYP2A6 2461/4885HTR2A 4364/4885 |
| US-11591354-B2 | Thiamine compound, preparation method and pharmaceutical composition thereof | SLC19A2, APP, BACE1 | CYP1A2 182/4885CYP2A6 205/4885HTR2A 324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.